G
General Proximity
Innovative drug discovery platform advancing next-gen induced proximity medicines
About General Proximity
Weatherwax Biotechnologies is a seed stage drug discovery platform company focused on developing the next generation of induced proximity medicines. The company operates in the biotechnology and pharmaceutical sectors, primarily serving clients in the medical and healthcare industries. By leveraging cutting-edge research and development, Weatherwax aims to create novel therapeutic solutions that address unmet medical needs.
The company's founders, Armand Cognetta and Matthias Pauthner, have a strong academic background with extensive experience in renowned labs at Scripps Research in San Diego. They have published over 50 papers in high-ranking academic journals such as Cell, Nature, Science, and The New England Journal of Medicine, and hold numerous patents in drug discovery.
Weatherwax Biotechnologies generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its proprietary drug candidates. The business model focuses on early-stage drug discovery and development, aiming to advance promising compounds through preclinical and clinical stages, either independently or in collaboration with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Francisco, United States
- Employees
- 23
- Open positions
- 4
- Dealroom signal
- 81.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Longevity, YC W20, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2026 | $0 | — | FreeMind Investments | A Venture Capital Fund · Daewoong Pharmaceutical Company | ↗ |
| SEED✓Equity / VC | Jan 2025 | $16M | $64M | Juan Benet · Age1 · Uri Lopatin · Jeff Dean | ↗ |
Growth signals
Latest recorded traffic for General Proximity is 4.2K monthly website visits, down 4.5% over the last three months. General Proximity's team grew 15% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed13 investors entered at this stage
Y Combinator
Bossa Invest
Coughdrop Capital
Felicis
Juan Benet
Age1- ULUri Lopatin
Jeff Dean
Trevor Martin
Modi Venture Partners
Wilson Sonsini
Alec Nielsen
Benjamin Mann
Series A2 investors entered at this stage
FreeMind Investments | A Venture Capital Fund
Daewoong Pharmaceutical Company
Other known investors2 additional known investors
Healthspan Capital
MBC Biolabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about General Proximity on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See General Proximity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.